HAVCR2 and acute myeloid leukemia: Most studies indicated that overexpression of TIM-3 either on immune cells or tumor cells is associated with poor OS for patients, such as patients with GC [88], and high-risk groups, showing poor prognosis, and lower complete response (CR) rates following induction chemotherapy in patients with AML as well as high-risk patients with B cell acute lymphoblastic lymphoma (B-ALL) relapse after allogeneic hematopoietic stem cell transplantation (allo-HSCT) [97–100].